Following Richmond Pharmacology�s Chief Executive Officer and Principal Investigator Dr Jorg Taubel�s presentation at the recent 2nd DIA Cardiac Safety Workshop in Japan, further data will be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), taking place 1st to 3rd December 2011, at Act City Hamamatsu.This year�s annual scientific meeting will assess the latest trends in clinical pharmacology and, as a first, will be jointly hosted by the three societies of the Japanese Society of Clinical Pharmacology and Therapeutics (JPCPT), the Korean Society of Clinical Pharmacology and Therapeutics (KSCPT) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT).Dr Taubel�s poster presentation session will provide an update on the original research carried out by Richmond Pharmacology, and is scheduled for Thursday, 1st December between 14:15 and 15:10:
- Alternative Methods for the Confirmation of Assay Sensitivity in Thorough QT Studies (Program number: 1-P-77)
- QT Prolongation in Healthy Japanese Subjects Receiving Moxifloxacin in Thorough QT Studies (Program number: 1-P-78)
- Sex Differences of the Effect of Moxifloxacin - A Meta -analysis of Five thorough QT Studies (Program number: 1-P-79)
Our total success rate in all Thorough QT studies reported to date confirms that we are a leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.For further information on our cardiac safety expertise and other specialist services please speak to a company representative at booth number 5, where we will be available to discuss how Richmond can benefit your prospective Phase I/II study requirements.We look forward to seeing you in Tokyo.